{"denoms":[{"counts":[{"groupId":"BG000","value":"463"}],"units":"Participants"}],"groups":[{"description":"Participants received Niraparib (300 milligram \\[mg\\], taken as 3 capsules of 100 mg once daily \\[QD\\]) orally beginning on Day 1 of every cycle (28 days) until treatment discontinuation.","id":"BG000","title":"Niraparib 300 mg"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.28","value":"64.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"463"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"394"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Black"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"32"}],"title":"Unknown"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Baseline characteristics were reported for Safety Population."}